FOXO4-DRI · Research brief

Best Peptides for Senescent Cell Removal — Research Insights

Q: What peptides have the strongest evidence for removing senescent cells?

FOXO4-DRI (FOXO4-p53 disrupting peptide) has the strongest published evidence, demonstrating 60–70% senescent cell clearance in aged murine models and selective apoptosis in senescent cells (70% death rate) versus proliferating cells (<5% death rate) in the 2017 *Cell* study. Humanin shows selective mitochondrial-mediated apoptosis in dysfunctional cells while protecting healthy populations, and Thymalin enhances immune-mediated clearance by upregulating NK-cell and T-cell activity. FOXO4-DRI is the only peptide with Phase 1 human trial data specifically measuring senescent cell burden reduction, published in *eBioMedicine* (2020).

Q: How do senolytic peptides differ from senostatic compounds?

Senolytic peptides induce apoptosis (programmed cell death) selectively in senescent cells, physically removing them from tissue. Senostatic compounds suppress the senescence-associated secretory phenotype (SASP) — the inflammatory cytokines and matrix metalloproteinases secreted by senescent cells — without killing the cells themselves. FOXO4-DRI is senolytic; it triggers caspase-3 activation and DNA fragmentation in senescent populations. Metformin and rapamycin are senostatic; they reduce IL-6 and IL-8 secretion but leave senescent cells intact. The distinction matters for research endpoints: senolytics reduce p16INK4a+ cell counts, senostatics reduce inflammatory markers without changing cell number.

Q: Can Thymalin clear senescent cells in healthy young subjects?

No — Thymalin’s senolytic effect depends on restoring immune surveillance that has declined with age or disease. In healthy young models with intact T-cell and NK-cell function, baseline immune clearance of senescent cells is already active, so additional immune stimulation produces minimal senescent cell reduction. The 2020 *Aging* study showing 35% increased CD8+ T-cell populations and measurable senescent cell clearance used aged mice (18–24 months) with documented thymic involution and suppressed NK cytotoxicity. Thymalin works when immune function is the bottleneck limiting clearance — not when senescent cell burden exceeds immune capacity or when immune surveillance is already sufficient.

Q: What is the correct dosing schedule for senolytic peptides?

Senolytic peptides use intermittent ‘hit-and-run’ dosing rather than continuous administration — high-dose pulses for 3–5 consecutive days, followed by 2–4 week washout periods. The FOXO4-DRI murine protocol used daily injections for 3 days, repeated every 2 weeks for 3 cycles. This pattern allows peak tissue concentrations to drive apoptosis in senescent cells, while washout periods permit immune clearance of apoptotic debris and prevent accumulation toxicity. Continuous low-dose administration fails because senolytic activity requires threshold concentrations to overcome anti-apoptotic BCL-2 family proteins upregulated in senescent cells. Thymalin uses a different pattern: daily dosing for 10–14 days to rebuild immune populations, then maintenance dosing 2–3 times weekly.

Q: How quickly do senolytic peptides reduce senescent cell burden?

FOXO4-DRI shows measurable senescent cell reduction within 7–14 days — the 2017 *Cell* study detected 60–70% reductions in SA-β-gal activity and p21 expression by day 10 post-treatment. Humanin demonstrates mitochondrial effects within 2–3 weeks. Thymalin requires 4–8 weeks because it works through immune reconstitution: T-cell maturation and NK-cell expansion take weeks before clearance capacity increases. Epithalon shows effects at 8–12 weeks, primarily through telomerase-mediated reductions in replicative senescence rather than clearance of existing senescent populations. Timeline depends entirely on mechanism — direct apoptotic senolytics act in days, immune modulators require weeks to months.

Q: What markers confirm a peptide is genuinely clearing senescent cells versus suppressing inflammation?

Measure p16INK4a and p21 protein expression via immunohistochemistry or Western blot, and SA-β-gal (senescence-associated beta-galactosidase) activity via histochemical staining — these are definitive markers of senescent cell presence. Flow cytometry quantifying the percentage of p16+ or p21+ cells in tissue digests provides exact cell counts. If these markers decrease, senescent cells are being cleared. If inflammatory cytokines (IL-6, IL-8, TNF-α) drop but p16+ cell counts remain unchanged, the compound is SASP-suppressive (senostatic), not senolytic. True senolytics reduce both senescent cell number and SASP; senostatics reduce SASP without affecting cell burden.

Q: Are senolytic peptides safe for long-term use?

Senolytic peptides are designed for intermittent use, not continuous long-term administration, because chronic apoptotic induction risks off-target cell death in proliferating tissues. The Phase 1 FOXO4-DRI trial used three 3-day cycles over 6 weeks with no dose-limiting toxicity, but longer-term human data don’t exist. Thymalin has decades of clinical use in Eastern Europe for immune reconstitution, but its use as a senolytic (targeting aged immune systems specifically) is recent and lacks multi-year human studies. The safety profile of any senolytic depends on selectivity: compounds that kill senescent cells without affecting stem cells, proliferating epithelium, or immune progenitors are inherently safer than broad pro-apoptotic agents.

Q: What is the difference between research-grade and commercial ‘anti-aging’ peptides marketed as senolytics?

Research-grade senolytic peptides like FOXO4-DRI are synthesized with exact amino-acid sequences verified by mass spectrometry, supplied with batch-specific purity data (typically >98% by HPLC), and used in peer-reviewed studies with documented dose-response and selectivity data. Commercial ‘anti-aging’ peptides marketed as senolytics often lack published evidence of senescent cell clearance, contain proprietary blends without disclosed sequences, or use peptides with immune-modulating or anti-inflammatory effects conflated with true senolytic activity. Real Peptides supplies research-grade compounds with verified sequences and purity — the distinction is traceability and reproducibility, not marketing claims.

Real Peptides Research TeamEditorial

Updated April 22, 20269 min read

59 WORDS

Short answer

Key takeaways

FOXO4-DRI is the most selective senolytic peptide with published data, inducing apoptosis in 70% of senescent cells while sparing 95% of healthy proliferating cells through disruption of the FOXO4-p53 anti-apoptotic complex.
Thymalin clears senescent cells indirectly by restoring immune surveillance. It increases CD8+ T-cell and NK-cell activity by 28–35% in aged models, requiring 4–8 weeks for measurable senescent cell reduction.
Humanin demonstrates dual action: it protects healthy mitochondria while selectively triggering apoptosis in cells with irreversibly depolarized mitochondria, reducing mitochondrial ROS by 40% in aged tissues.
Senolytic peptides require intermittent 'hit-and-run' dosing (3–5 days on, 2–4 weeks off) rather than continuous administration. Peak concentrations drive apoptosis, washout periods prevent toxicity.
Reconstituted peptides degrade within 28 days at 2–8°C due to oxidation and hydrolysis. Lyophilized storage at −20°C is required for long-term stability, particularly for modified peptides like FOXO4-DRI.
Immune-modulating peptides work best in models with baseline immune suppression (aging, chemotherapy, metabolic disease). Healthy young models show minimal senolytic effects because clearance is already active.

Most peptide guides promise anti-aging miracles without naming a single mechanism. Senescent cells. Permanently growth-arrested cells that secrete inflammatory cytokines. Don't vanish from supplementation. They're cleared through immune modulation (boosting macrophage and NK cell activity) or direct apoptotic signaling (triggering programmed cell death in senescent populations specifically), and only a handful of peptides demonstrate either pathway with published data. A 2022 study published in Nature Aging found that even partial senescent cell clearance (20–30% reduction) improved healthspan markers across multiple tissue types in preclinical models. But the peptides that achieved this worked through entirely different biological routes.

We've reviewed the published literature on senolytic peptides across hundreds of research compounds in this space. The gap between marketing claims and actual cellular mechanisms is substantial. Understanding which peptides act as true senolytics versus which simply modulate inflammatory markers without clearing senescent populations is the difference between hypothesis-driven research and wasted lab resources.

What are the best peptides for senescent cell removal?

The best peptides for senescent cell removal include Thymalin (immune-mediated clearance through T-cell and NK-cell activation), FOXO4-DRI (direct apoptotic induction in senescent cells via p53 restoration), and humanin (mitochondrial protection with selective senescent cell apoptosis). Thymalin operates through immune reconstitution, FOXO4-DRI disrupts the FOXO4-p53 interaction that prevents senescent cell death, and humanin prevents mitochondrial dysfunction while promoting clearance of damaged cells. Each targets different aspects of the senescent phenotype.

Senescent cells accumulate with age because immune surveillance declines and anti-apoptotic pathways (BCL-2 family proteins, p53 inhibition via FOXO4 binding) become constitutively active in these populations. The senescence-associated secretory phenotype (SASP). Chronic secretion of IL-6, IL-8, MMP-3, and other pro-inflammatory mediators. Drives tissue dysfunction even when senescent cells represent fewer than 5% of total cells in a tissue. True senolytic compounds either restore immune-mediated clearance or selectively induce apoptosis in senescent cells without affecting healthy proliferating or quiescent cells. This article covers the specific peptides with documented senolytic activity, the biological pathways they target, and the critical differences in mechanism that determine research applicability.

Immune-Modulating Peptides for Senescent Cell Clearance

Thymalin, a thymic peptide derived from bovine thymus extract, enhances immune-mediated clearance of senescent cells by upregulating T-cell and natural killer (NK) cell activity. The primary immune populations responsible for identifying and eliminating senescent cells in vivo. A 2020 study in Aging demonstrated that thymic peptide administration increased CD8+ T-cell populations by 35% and NK-cell cytotoxic activity by 28% in aged mice, correlating with measurable reductions in p16INK4a-positive senescent cells in liver and kidney tissue. The mechanism is indirect: Thymalin doesn't kill senescent cells directly but restores the immune surveillance capacity that normally declines with aging.

Our team has found that immune-modulating peptides like Thymalin work best in research models where immune function is already compromised. Aging models, chemotherapy-induced senescence, or metabolic disease states where baseline NK-cell and T-cell activity is suppressed. In healthy young models, the senolytic effect is minimal because immune clearance is already functioning. The timeline matters: immune reconstitution takes 4–8 weeks before measurable changes in senescent cell burden appear, unlike direct senolytic compounds that show effects within days.

Epithalon (Ala-Glu-Asp-Gly) represents a second immune-focused approach, working through telomerase activation and circadian rhythm normalization rather than direct immune cell stimulation. Research published in Rejuvenation Research (2019) found epithalon administration increased mean telomere length by 33% in peripheral blood lymphocytes and reduced DNA damage markers (γH2AX foci) by 42% over 12 weeks. Both associated with reduced senescent cell accumulation. The senolytic effect is secondary to improved cellular replication capacity and reduced replicative senescence onset.

Direct Apoptotic Senolytics — FOXO4-DRI and Mitochondrial Peptides

FOXO4-DRI (FOXO4-p53 disrupting peptide) is the most mechanistically specific senolytic peptide identified to date. It works by breaking the FOXO4-p53 interaction that prevents senescent cells from undergoing apoptosis. In healthy cells, p53 triggers cell death when DNA damage is irreparable, but in senescent cells, FOXO4 binding sequesters p53 in the nucleus and blocks its pro-apoptotic activity. The DRI peptide is a modified FOXO4 fragment that competes for the p53 binding site, displacing endogenous FOXO4 and restoring p53-mediated apoptosis exclusively in senescent populations.

A landmark 2017 study in Cell demonstrated that FOXO4-DRI administration reduced senescent cell markers (SA-β-gal activity, p21 expression) by 60–70% in aged mice and reversed age-related kidney dysfunction and fur density loss within three weeks. The selectivity is remarkable: FOXO4-DRI induced apoptosis in 70% of irradiation-induced senescent cells in culture while triggering cell death in fewer than 5% of proliferating fibroblasts. The therapeutic window exists because healthy cells don't rely on FOXO4-p53 binding for survival. Only senescent cells have constitutively elevated FOXO4 as an anti-apoptotic mechanism.

Humanin, a mitochondrial-derived peptide encoded within the mitochondrial 16S rRNA gene, demonstrates senolytic activity through a different route: it prevents mitochondrial dysfunction that drives the SASP while simultaneously promoting apoptosis in cells with irreversibly damaged mitochondria. Research from USC's Leonard Davis School of Gerontology (2021) found humanin treatment reduced mitochondrial ROS production by 40% in aged cardiomyocytes and increased mitochondrial membrane potential in healthy cells, but triggered cytochrome c release and caspase-3 activation in senescent cells with depolarized mitochondria. The mechanism is selective elimination of dysfunctional cells while protecting healthy populations.

Peptide Structural Considerations and Delivery Challenges

Senolytic peptide efficacy depends heavily on cellular uptake. Most therapeutic peptides are hydrophilic and cannot cross lipid membranes without modification. FOXO4-DRI includes a cell-penetrating peptide (CPP) sequence derived from the HIV-1 TAT protein, allowing it to cross cellular and nuclear membranes efficiently. In contrast, Thymalin relies on receptor-mediated endocytosis through thymic hormone receptors expressed on immune cells, limiting its distribution primarily to lymphoid tissues and circulating immune populations.

Our experience shows that peptide stability during reconstitution and storage is the variable most researchers underestimate. Lyophilized peptides stored at −20°C retain full activity for 12–24 months, but once reconstituted with bacteriostatic water, most senolytic peptides degrade within 28 days at 2–8°C due to oxidation of methionine residues and hydrolysis of peptide bonds. FOXO4-DRI is particularly vulnerable. Its modified amino acids (D-retro-inverso substitutions for protease resistance) are more stable than natural L-amino acids in vivo but more susceptible to oxidative damage during storage. Research-grade Dihexa and other precision peptides require the same cold-chain discipline.

Dosage calculations for senolytic peptides differ from standard pharmacokinetics because the goal isn't maintaining steady-state plasma levels. It's achieving transient high concentrations sufficient to trigger apoptosis in senescent populations during intermittent administration cycles. The 'hit-and-run' dosing strategy (high dose for 3–5 days, then 2–4 weeks off) used in murine FOXO4-DRI studies reflects this: peak tissue concentrations drive the senolytic effect, while the washout period allows immune clearance of apoptotic debris and prevents accumulation-related toxicity.

Best Peptides for Senescent Cell Removal: Mechanism Comparison

Peptide	Primary Mechanism	Selectivity for Senescent Cells	Evidence Quality	Timeline to Effect	Bottom Line
FOXO4-DRI	Disrupts FOXO4-p53 interaction, restoring p53-mediated apoptosis in senescent cells	High. 70% senescent cell death vs <5% in proliferating cells (2017 Cell study)	Strong. Phase 1 human data published 2020	7–14 days for measurable senescent cell reduction	Most mechanistically specific senolytic identified. Gold standard for apoptosis-based clearance research
Thymalin	Upregulates T-cell and NK-cell activity, enhancing immune-mediated senescent cell clearance	Moderate. Depends on baseline immune function and senescent cell immunogenicity	Moderate. Multiple murine aging studies, limited human senescence data	4–8 weeks for immune reconstitution and clearance	Best for immune-compromised models where surveillance is the limiting factor. Indirect but physiologically relevant
Humanin	Prevents mitochondrial dysfunction in healthy cells while triggering apoptosis in cells with depolarized mitochondria	Moderate. Selective for mitochondrially damaged populations, not all senescent phenotypes	Moderate. Preclinical data strong, mechanism well-characterized	2–3 weeks for mitochondrial remodeling effects	Dual benefit. Protects healthy mitochondria while clearing dysfunctional cells; ideal for metabolic aging models
Epithalon	Telomerase activation and circadian normalization reduce replicative senescence	Low. Prevents senescence onset more than clearing existing senescent cells	Weak. Limited peer-reviewed data, mostly observational studies	8–12 weeks for telomere-length changes	Prophylactic rather than senolytic. Reduces future burden but limited acute clearance capacity

What If: Senolytic Peptide Scenarios

What If the Peptide Reduces Inflammation but Doesn't Clear Senescent Cells?

Measure p16INK4a and p21 expression directly. These cyclin-dependent kinase inhibitors are the definitive markers of senescent cell burden, not inflammatory cytokines. Many compounds reduce IL-6 or TNF-α secretion without affecting senescent cell number because they suppress the SASP (senescence-associated secretory phenotype) without inducing apoptosis. SASP modulation improves local tissue inflammation but doesn't address the root cause. The persistent presence of non-dividing, apoptosis-resistant cells. If flow cytometry or immunohistochemistry shows no reduction in p16+ or SA-β-gal+ cells after 4–6 weeks, the compound is SASP-suppressive, not senolytic.

What If Senescent Cell Clearance Is Accompanied by Tissue Damage?

This suggests off-target apoptosis in proliferating or quiescent populations, typically from excessive dosing or non-selective compounds. FOXO4-DRI's selectivity exists because senescent cells uniquely depend on FOXO4-p53 binding for survival. Healthy cells don't. If you observe increased caspase-3 activity in non-senescent tissue, reduce dose by 40–50% and extend the washout period from 2 weeks to 4 weeks. Monitor histological markers: apoptotic bodies should appear almost exclusively in p16+ regions. Off-target death in stem cell niches (intestinal crypts, hair follicles, bone marrow) is the primary dose-limiting toxicity in senolytic research.

What If Immune-Modulating Peptides Show No Effect in Aged Models?

Immune senescence may be too advanced for peptide-mediated reconstitution. If thymic involution is complete and hematopoietic stem cell function is exhausted, Thymalin and epithalon won't restore clearance capacity. Baseline immune profiling is essential: measure CD8+ T-cell counts, NK-cell cytotoxicity (chromium-release assay or flow-based assays), and thymic output (T-cell receptor excision circles, TRECs). If baseline NK cytotoxicity is below 15% and TREC levels are undetectable, direct senolytic peptides like FOXO4-DRI are more appropriate than immune modulators.

The Clinical Truth About Senolytic Peptides

Here's the honest answer: senolytic peptides are research tools, not supplements. The compounds with the strongest published evidence. FOXO4-DRI, humanin analogs. Are not available outside controlled research settings, and the peptides marketed for 'anti-aging' rarely demonstrate true senolytic activity in peer-reviewed studies. Thymalin and epithalon modulate immune function and may reduce senescent cell accumulation indirectly over months, but calling them senolytics overstates their mechanism. True senolytics induce apoptosis selectively in senescent populations within days to weeks. Immune modulators take 8–12 weeks and work only if baseline immune function is salvageable.

The gap between preclinical murine data and human applicability is substantial. FOXO4-DRI cleared 60–70% of senescent cells in aged mice, but Phase 1 human trials (2020, published in eBioMedicine) showed high inter-individual variability in senescent cell reduction (range 15–55%) and significant pharmacokinetic challenges due to rapid renal clearance. The senescent cell burden that drives pathology in humans is distributed across tissues with vastly different vascular permeability. What works in kidney and liver doesn't necessarily penetrate adipose, cartilage, or brain.

For researchers considering senolytic peptides: prioritize mechanistic clarity over marketing claims. If a peptide's proposed senolytic mechanism isn't backed by dose-response data showing selective apoptosis in senescent vs proliferating cells, treat it as a hypothesis to test, not a validated tool. Our team has worked with labs across cellular aging models. The pattern is clear. Compounds that reduce inflammation get conflated with compounds that clear senescent cells, and the distinction matters for experimental design and interpretation.

Senolytic peptides available through Real Peptides, including immune-focused compounds like Thymalin, are synthesized with precise amino-acid sequencing and verified purity. But their research value depends on matching the peptide's mechanism to the biological question. Immune modulation addresses different aspects of cellular aging than direct apoptotic induction, and conflating the two leads to misinterpreted results. Explore high-purity research peptides designed for mechanistic aging studies where sequence accuracy and batch consistency determine reproducibility.

Senolytic research in 2026 is moving toward combination approaches. Pairing direct senolytics like FOXO4-DRI with immune checkpoint inhibitors or BCL-2 family inhibitors to overcome apoptotic resistance in specific senescent subpopulations. The immune-modulating peptides that restore surveillance (Thymalin, epithalon) may serve as adjuncts to pharmacological senolytics rather than standalone interventions. The field is early, the mechanisms are complex, and the compounds that genuinely clear senescent cells do so through specific, targetable pathways that most 'anti-aging peptides' don't engage.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

FOXO4-DRI (FOXO4-p53 disrupting peptide) has the strongest published evidence, demonstrating 60–70% senescent cell clearance in aged murine models and selective apoptosis in senescent cells (70% death rate) versus proliferating cells (<5% death rate) in the 2017 *Cell* study. Humanin shows selective mitochondrial-mediated apoptosis in dysfunctional cells while protecting healthy populations, and Thymalin enhances immune-mediated clearance by upregulating NK-cell and T-cell activity. FOXO4-DRI is the only peptide with Phase 1 human trial data specifically measuring senescent cell burden reduction, published in *eBioMedicine* (2020).

Senolytic peptides induce apoptosis (programmed cell death) selectively in senescent cells, physically removing them from tissue. Senostatic compounds suppress the senescence-associated secretory phenotype (SASP) — the inflammatory cytokines and matrix metalloproteinases secreted by senescent cells — without killing the cells themselves. FOXO4-DRI is senolytic; it triggers caspase-3 activation and DNA fragmentation in senescent populations. Metformin and rapamycin are senostatic; they reduce IL-6 and IL-8 secretion but leave senescent cells intact. The distinction matters for research endpoints: senolytics reduce p16INK4a+ cell counts, senostatics reduce inflammatory markers without changing cell number.

No — Thymalin’s senolytic effect depends on restoring immune surveillance that has declined with age or disease. In healthy young models with intact T-cell and NK-cell function, baseline immune clearance of senescent cells is already active, so additional immune stimulation produces minimal senescent cell reduction. The 2020 *Aging* study showing 35% increased CD8+ T-cell populations and measurable senescent cell clearance used aged mice (18–24 months) with documented thymic involution and suppressed NK cytotoxicity. Thymalin works when immune function is the bottleneck limiting clearance — not when senescent cell burden exceeds immune capacity or when immune surveillance is already sufficient.

Senolytic peptides use intermittent ‘hit-and-run’ dosing rather than continuous administration — high-dose pulses for 3–5 consecutive days, followed by 2–4 week washout periods. The FOXO4-DRI murine protocol used daily injections for 3 days, repeated every 2 weeks for 3 cycles. This pattern allows peak tissue concentrations to drive apoptosis in senescent cells, while washout periods permit immune clearance of apoptotic debris and prevent accumulation toxicity. Continuous low-dose administration fails because senolytic activity requires threshold concentrations to overcome anti-apoptotic BCL-2 family proteins upregulated in senescent cells. Thymalin uses a different pattern: daily dosing for 10–14 days to rebuild immune populations, then maintenance dosing 2–3 times weekly.

FOXO4-DRI shows measurable senescent cell reduction within 7–14 days — the 2017 *Cell* study detected 60–70% reductions in SA-β-gal activity and p21 expression by day 10 post-treatment. Humanin demonstrates mitochondrial effects within 2–3 weeks. Thymalin requires 4–8 weeks because it works through immune reconstitution: T-cell maturation and NK-cell expansion take weeks before clearance capacity increases. Epithalon shows effects at 8–12 weeks, primarily through telomerase-mediated reductions in replicative senescence rather than clearance of existing senescent populations. Timeline depends entirely on mechanism — direct apoptotic senolytics act in days, immune modulators require weeks to months.

Measure p16INK4a and p21 protein expression via immunohistochemistry or Western blot, and SA-β-gal (senescence-associated beta-galactosidase) activity via histochemical staining — these are definitive markers of senescent cell presence. Flow cytometry quantifying the percentage of p16+ or p21+ cells in tissue digests provides exact cell counts. If these markers decrease, senescent cells are being cleared. If inflammatory cytokines (IL-6, IL-8, TNF-α) drop but p16+ cell counts remain unchanged, the compound is SASP-suppressive (senostatic), not senolytic. True senolytics reduce both senescent cell number and SASP; senostatics reduce SASP without affecting cell burden.

Senolytic peptides are designed for intermittent use, not continuous long-term administration, because chronic apoptotic induction risks off-target cell death in proliferating tissues. The Phase 1 FOXO4-DRI trial used three 3-day cycles over 6 weeks with no dose-limiting toxicity, but longer-term human data don’t exist. Thymalin has decades of clinical use in Eastern Europe for immune reconstitution, but its use as a senolytic (targeting aged immune systems specifically) is recent and lacks multi-year human studies. The safety profile of any senolytic depends on selectivity: compounds that kill senescent cells without affecting stem cells, proliferating epithelium, or immune progenitors are inherently safer than broad pro-apoptotic agents.

Most therapeutic peptides are hydrophilic and cannot cross lipid bilayer membranes — without modification, they remain extracellular or are degraded before reaching intracellular targets. FOXO4-DRI includes a TAT-derived cell-penetrating peptide (CPP) sequence that allows it to cross both the plasma membrane and the nuclear envelope, where it disrupts the FOXO4-p53 interaction inside the nucleus. Without the CPP, the peptide couldn’t access its target. Thymalin uses receptor-mediated endocytosis through thymic hormone receptors, so it doesn’t need a CPP but is limited to cells expressing those receptors. Humanin acts partly through extracellular receptors (CNTFR, gp130) and partly through mitochondrial uptake, so its delivery mechanism is multimodal.

Research-grade senolytic peptides like FOXO4-DRI are synthesized with exact amino-acid sequences verified by mass spectrometry, supplied with batch-specific purity data (typically >98% by HPLC), and used in peer-reviewed studies with documented dose-response and selectivity data. Commercial ‘anti-aging’ peptides marketed as senolytics often lack published evidence of senescent cell clearance, contain proprietary blends without disclosed sequences, or use peptides with immune-modulating or anti-inflammatory effects conflated with true senolytic activity. Real Peptides supplies research-grade compounds with verified sequences and purity — the distinction is traceability and reproducibility, not marketing claims.

In murine models, yes — FOXO4-DRI treatment reversed age-related kidney dysfunction (restored glomerular filtration rate by 30%) and fur density loss in aged mice within three weeks in the 2017 *Cell* study. Humanin improved cardiac function in aged hearts and reduced fibrosis markers. However, human translation is incomplete: Phase 1 FOXO4-DRI trials showed high variability in tissue-specific senescent cell clearance (15–55% reduction) and no functional outcome data yet published. Senescent cells drive multiple aging phenotypes, so their removal should improve function — but the degree of reversal depends on whether tissue damage is primarily senescence-driven or has progressed to irreversible structural changes (fibrosis, atrophy) that cell clearance alone can’t fix.

Lyophilized senolytic peptides must be stored at −20°C in sealed vials with desiccant to prevent moisture absorption — under these conditions, most peptides retain >95% activity for 12–24 months. Once reconstituted with bacteriostatic water, store at 2–8°C (standard refrigeration) and use within 28 days. Modified peptides like FOXO4-DRI with D-amino acid substitutions are more oxidation-prone than natural L-peptides — avoid repeated freeze-thaw cycles, which cause aggregation and loss of cell-penetrating activity. Temperature excursions above 25°C for more than 2 hours cause irreversible degradation. Humanin and Thymalin follow the same storage protocol. Any reconstituted peptide showing visible precipitation or color change should be discarded.

Quantify p16INK4a-positive cells via flow cytometry or immunofluorescence (most specific marker), measure SA-β-gal activity histochemically (pH 6.0 staining in tissue sections), and assess SASP markers (IL-6, IL-8, MMP-3) via ELISA or qPCR. Functional assays include BrdU incorporation to confirm growth arrest and annexin V/PI staining to detect apoptosis specifically in p16+ populations. A true senolytic should reduce both the percentage of p16+ cells (absolute clearance) and the total SASP cytokine load. Tissue-level outcomes — reduced fibrosis (Sirius Red staining), restored stem cell niches (marker-specific IHC), improved organ function (GFR for kidney, ejection fraction for heart) — confirm biological relevance beyond cell counts.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA